<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217292</url>
  </required_header>
  <id_info>
    <org_study_id>2011-KAEK-25 2016/13-06</org_study_id>
    <nct_id>NCT03217292</nct_id>
  </id_info>
  <brief_title>Serratus Anterior Plane Block for Pain Treatment After Video-Assisted Thoracoscopic Surgery</brief_title>
  <official_title>Evaluation of the Effect of Serratus Anterior Plane Block for Pain Treatment After Video-Assisted Thoracoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Yüksek İhtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Yüksek İhtisas Education and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analgesia following video-assisted thoracoscopic surgery (VATS) is important for the
      prevention of postoperative pulmonary complications.Various regional methods of anesthesia
      are currently being used to achieve this goal. The aim of the study was to assess the
      effectiveness of SAPB on postoperative VATS analgesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, controlled, single-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <description>Visual Analogue Scale was used for pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tramadol consumption</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>tramadol consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation scale (RSS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Ramsay sedation scale (RSS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>side effect profile</measure>
    <time_frame>24 hours</time_frame>
    <description>side effect profile</description>
  </other_outcome>
  <other_outcome>
    <measure>additional analgesic use</measure>
    <time_frame>24 hours</time_frame>
    <description>additional analgesic use</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Group S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serratus Anterior Plane Block</intervention_name>
    <arm_group_label>Group S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV patient-controlled analgesia (PCA) tramadol</intervention_name>
    <arm_group_label>Group S</arm_group_label>
    <arm_group_label>Group T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were in the American Society of Anesthesiologists (ASA) I-III class and
             underwent video-assisted thoracoscopic surgery (VATS).

        Exclusion Criteria:

          -  Previous history of opioid use preoperatively,

          -  Allergy to local anesthetics,

          -  The presence of any systemic infection,

          -  Uncontrolled arterial hypertension,

          -  Uncontrolled diabetes mellitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burcu Metin Ökmen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital</affiliation>
  </overall_official>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bursa Yüksek İhtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Korgün Ökmen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

